Original Research
Published on 20 Dec 2024
Cost-effectiveness analysis of first-line combination chemotherapy regimens for metastatic pancreatic cancer and evidence-based pricing strategy of liposomal irinotecan in China
in Drugs Outcomes Research and Policies